Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + IE in Relapsed/Refractory Osteosarcoma
NCT05277480Phase 2Completed
- Sponsor
- Peking University People's Hospital
- Start
- Mar 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in osteosarcoma (OS), sponsored by Peking University People's Hospital. Started Mar 2022; status: completed.
02
Drugs
Rivoceranib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT05277480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05277480.